- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00002026
Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)
June 23, 2005 updated by: Glaxo Wellcome
To evaluate the efficacy of oral acyclovir for the treatment and suppression of Epstein-Barr virus (EBV) related hairy leukoplakia (HL).
To determine the long-term safety of acyclovir in the AIDS-related complex (ARC) patient with HL.
To monitor the progression of HIV disease in the HL patient and compare to existing historical control data.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Los Angeles, California, United States, 900331079
- Univ of Southern California / LA County USC Med Ctr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria
Concurrent Medication:
Allowed:
- Topical antifungal therapy.
Patient must have:
- Newly diagnosed clinical and histological hairy leukoplakia.
- Positive HIV antibody by licensed ELISA or Western blot.
Exclusion Criteria
Co-existing Condition:
Patients with AIDS or a history of intolerance or allergy to acyclovir are excluded.
Concurrent Medication:
Excluded within 2 weeks of study entry:
- Systemic antifungal treatment.
- Excluded within 6 weeks of study entry:
- Immunomodulators.
- Systemic antiviral treatment.
Patients with AIDS or a history of intolerance or allergy to acyclovir are excluded.
Prior Medication:
Excluded within 2 weeks of study entry:
- Systemic antifungal.
- Excluded within 6 weeks of study entry:
- Immunomodulators.
- Systemic antiviral treatment.
- Excluded within 8 weeks of study entry:
- Zidovudine (AZT) or other antiretroviral therapy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
November 2, 1999
First Submitted That Met QC Criteria
August 30, 2001
First Posted (Estimate)
August 31, 2001
Study Record Updates
Last Update Posted (Estimate)
June 24, 2005
Last Update Submitted That Met QC Criteria
June 23, 2005
Last Verified
May 1, 1990
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Virus Diseases
- Infections
- Neoplasms
- Neoplasms by Site
- Head and Neck Neoplasms
- Stomatognathic Diseases
- Mouth Diseases
- DNA Virus Infections
- Pathological Conditions, Anatomical
- Precancerous Conditions
- Epstein-Barr Virus Infections
- Herpesviridae Infections
- Mouth Neoplasms
- Leukoplakia, Oral
- Leukoplakia
- Leukoplakia, Hairy
- Anti-Infective Agents
- Antiviral Agents
- Acyclovir
Other Study ID Numbers
- 033A
- 179
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Acyclovir
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)Completed
-
University of WashingtonNational Institutes of Health (NIH)Completed
-
National Center for Research Resources (NCRR)National Institute of Allergy and Infectious Diseases (NIAID)Completed
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingInvasive Mechanical Ventilation | HSV Throat Reactivation
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedHerpes SimplexUnited States
-
Centers for Disease Control and PreventionMinistry of Health, ThailandCompleted
-
National Center for Research Resources (NCRR)University of Alabama at BirminghamCompletedHerpes SimplexUnited States, Canada
-
National Center for Research Resources (NCRR)National Institute of Allergy and Infectious Diseases (NIAID)Completed
-
University of WashingtonNational Institute of Allergy and Infectious Diseases (NIAID)Terminated
-
University of WashingtonNational Institutes of Health (NIH)CompletedGenital HerpesUnited States